Fycompa
Generalized Epilepsy
Chinese University of Hong KongDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Generalized Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BBB |
MELATONIN All India Institute of Medical Sciences, Bhubaneswar | Phase 4 | BB |
Clobazam Lundbeck LLC | Phase 3 | BB |
Cenobamate Ono Pharmaceutical Co., Ltd. | Phase 3 | BB |
Diazepam Pfizer | Phase 3 | B |
View all 11 →
Same molecule, other indications
Fycompa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →